Skip to main content

BeyondSpring, Inc. (BYSI)

NASDAQ: BYSI · IEX Real-Time Price · USD
16.19 -0.56 (-3.34%)
Oct 21, 2021 1:32 PM EDT - Market open
Market Cap675.54M
Revenue (ttm)856,000
Net Income (ttm)-68.43M
Shares Out39.01M
EPS (ttm)-1.92
PE Ration/a
Forward PE10.54
Dividendn/a
Ex-Dividend Daten/a
Volume319,663
Open16.75
Previous Close16.75
Day's Range16.04 - 16.87
52-Week Range8.90 - 33.00
Beta1.12
AnalystsStrong Buy
Price Target65.60 (+305.2%)
Est. Earnings DateNov 17, 2021

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in...

IndustryBiotechnology
IPO DateMar 9, 2017
Employees91
Stock ExchangeNASDAQ
Ticker SymbolBYSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for BeyondSpring stock is "Strong Buy." The 12-month stock price forecast is 65.60, which is an increase of 305.19% from the latest price.

Price Target
$65.60
(305.19% upside)
Analyst Consensus: Strong Buy

News

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in...

—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.

6 hours ago - GlobeNewsWire

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NC...

NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeuti...

1 day ago - GlobeNewsWire

Why Are BeyondSpring's Shares Plunging Today?

BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetaxel vs.

1 month ago - Benzinga

Here's why BeyondSpring shares are up more than 25% on Monday

Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung canc...

1 month ago - Invezz

BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination...

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeut...

1 month ago - GlobeNewsWire

BeyondSpring Presents New Plinabulin Data At ESMO Congress

BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Co...

1 month ago - Benzinga

BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prev...

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. Plinabulin in co...

1 month ago - GlobeNewsWire

BeyondSpring: Q2 Earnings Insights

BeyondSpring(NASDAQ:BYSI) stock fell by 4.13% on Monday after the company reported their Q2 earnings results on Friday, September 10, 2021 at 07:00 AM. Here's what investors need to know about the annou...

1 month ago - Benzinga

BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

- Management to host a call today at 8:00 am ET - Management to host a call today at 8:00 am ET

1 month ago - GlobeNewsWire

Baird Initiates BeyondSpring With Outperform On Plinabulin Potential

BeyondSpring Inc's (NASDAQ:BYSI) lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia (CIN), according to Baird. The BeyondSpring An...

1 month ago - Benzinga

BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at th...

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today annou...

1 month ago - GlobeNewsWire

BeyondSpring to Participate in the Upcoming September Conferences

NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announ...

1 month ago - GlobeNewsWire

BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?

Today, some very positive news surrounding BeyondSpring's lead drug candidate has sent shares of BYSI stock soaring. The post BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?

1 month ago - InvestorPlace

BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel C...

NEW YORK, Aug. 31, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announ...

1 month ago - GlobeNewsWire

Why BeyondSpring Stock Is Soaring This Week

A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug.

1 month ago - The Motley Fool

BeyondSpring Inks Plinabulin Agreement In Greater China

BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combination w...

1 month ago - Benzinga

BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals ...

NEW YORK and SHANGHAI, China, Aug. 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therap...

1 month ago - GlobeNewsWire

This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?

Don't be too quick to pull the trigger.

2 months ago - The Motley Fool

Why BeyondSpring's Stock Is Soaring Higher

BeyondSpring Inc (NASDAQ: BYSI) shares are trading higher by 22.5% at $26.59 Friday afternoon on continued strength after the company earlier in the week announced results from its DUBLIN-3 trial of pli...

2 months ago - Benzinga

Why BeyondSpring Stock Skyrocketed Today

The biotech's experimental cancer therapy could be a game-changer.

2 months ago - The Motley Fool

These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger

The Nasdaq Composite is holding up better than its fellow market benchmarks.

Other symbols:NVAX
2 months ago - The Motley Fool

BYSI Stock: The Huge Cancer News Sending BeyondSpring Skyrocketing Today

Shares of BYSI stock are soaring on Wednesday after pharmaceutical firm BeyondSpring released positive data regarding its lung cancer drug. The post BYSI Stock: The Huge Cancer News Sending BeyondSpring...

2 months ago - InvestorPlace

Why BeyondSpring's Stock Is Rallying Today

BeyondSpring Inc. (NASDAQ: BYSI) shares are trading higher after the company announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel for non-small cell lung cancer, which s...

2 months ago - Benzinga

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination w...

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced to...

2 months ago - GlobeNewsWire